8Miguel M.Platinum compounds in the treatment of advanced breast cancer[J].Clin Breast Cancer,2001,2(3):190-208.
9Vittorio G,Nicolo B,Antonio T,et al.Phase Ⅰ-Ⅱ parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma[J].Breast Cancer Res and Treatment,2003,77(2):99-108.
10Park SH,Cho EK,Bang SM,et al.Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment:a phase Ⅱ clinical trial[J].BMC Cancer,2005,22(5):21.
2Gurkan S, Seber S, Gur O, et al. Retrospective evaluation of totally implantable venous access port devices: early and late complica- tions [J]. J BUON, 2015, 20(1): 338-345.
3Wiegering V, Sehrnid S, Andres O, et al. Thrombosis as a complica- tion of central venous access in pediatric patients with malignan-cies: a 5-year single-center experience [J]. BMC Hematol, 2014, 14 (1): 18.
4Hiebl B, Hopperdietzel C, Hfinigen H, et al. Tissue reaction induced by implanted venous access ports in adult patients after infection of the implantation site [J]. Clin Hemorheol Microcirc, 2014, 58(1): 107-113.
5Suria S, Wyniecki A, Eghiaian A, et al. Measurement of cardiac in- dex by transpulmonary thermodilution using an implanted central venous access port: a prospective study in patients scheduled for 011- cologic high-risk surgery [J]. PLoS One, 2014, 9(8): e104369.
6Rouzrokh M, Shamsian BS, KhaleghNejad Tabari A, et al. Totally implantable sublectoral vs. subcutaneous port systems in chil-dren with malignant diseases[J]. Arch lran Med, 2009, 12 (4): 389.
